Atovaquone: a new antipneumocystis agent

Area of Science:

• Pharmacology
• Infectious Diseases
• Clinical Medicine

Background:

• Pneumocystis pneumonia (PCP) is a significant opportunistic infection.
• Traditional treatments for PCP include trimethoprim-sulfamethoxazole and pentamidine isethionate.
• Atovaquone presents a novel therapeutic option for PCP management.

Purpose of the Study:

• To review the mechanism of action, pharmacokinetics, pharmacodynamics, clinical efficacy, adverse effects, and dosage of atovaquone for mild to moderate PCP.
• To evaluate atovaquone's role in PCP treatment, particularly for patients intolerant to other therapies.

Main Methods:

• Review of existing literature on atovaquone for PCP.
• Analysis of comparative trials assessing atovaquone's efficacy and safety.
• Examination of pharmacokinetic data, including food-enhanced absorption.

Main Results:

• Atovaquone exhibits a unique microbicidal mechanism against Pneumocystis carinii.
• Drug absorption is significantly increased when taken with high-fat meals.
• Clinical efficacy is comparable to pentamidine isethionate and slightly lower than trimethoprim-sulfamethoxazole.
• Atovaquone demonstrates a lower incidence of adverse reactions compared to trimethoprim-sulfamethoxazole and pentamidine, with rash being the most common side effect.

Conclusions:

• Atovaquone is an effective treatment for mild to moderate PCP with a favorable safety profile.
• Its novel mechanism and good tolerability make it a viable alternative, especially for patients with acquired immunodeficiency syndrome (AIDS) intolerant to standard therapies.
• Optimal dosing involves 750 mg orally three times daily with food for 21 days.